Patents by Inventor Coline Legrand

Coline Legrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210196671
    Abstract: Compositions can comprise the catechin metabolite 3?-O-methyl-4?-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions may be administered orally as a food product in which the 3?-O-methyl-4?-O-sulfate epicatechinis present in a concentration of at least 0.01 mg/g of the food product.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 1, 2021
    Inventors: Lucas Actis Goretta, Amaury Paatin, Stephanie Michlig Gonzalez, Coline Legrand, Susana Camacho, Johannes Le Coutre
  • Publication number: 20210196672
    Abstract: Compositions can comprise the catechin metabolite 3?-O-methyl-5-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions are preferably administered orally as a food product in which the 3?-O-methyl-5-O-sulfateepicatechinis present in a concentration of at least 0.01 mg/g of the food product.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 1, 2021
    Inventors: Lucas Actis Goretta, Amaury Patin, Stephanie Michlig Gonzalez, Coline Legrand, Susana Camacho, Johannes Le Coutre
  • Publication number: 20200261485
    Abstract: Compositions can comprise the flavanol metabolite 3?-O-glucuronide epicatechin (3GEC). In some embodiments, the amount of 3GEC is effective to increase energy expenditure, sympathetic nervous system activity, and/or fat oxidation. Such a composition can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In some embodiments, the composition can improve insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood and/or memory. In some embodiments, the composition can achieve a therapeutic effect selected from the group consisting of blood vessel dilation, reduced blood pressure, increased delivery of blood flow to tissues in the body, improvement of blood circulation, e.g. in brain, stimulation of protein synthesis, increased release of growth factors, enhanced immune function, and combinations thereof. In some embodiments, the composition can treat or prevent dysphagia, e.g.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 20, 2020
    Inventors: Lucas Actis Goretta, Amaury Patin, Stephanie Michlig Gonzalez, Susana Camacho, Coline Legrand, Johannes Le Coutre, Euridice Castaneda Gutierrez, Irma Silva Zolezzi
  • Publication number: 20190000868
    Abstract: Compositions can comprise the flavanol metabolite 4?-O-glucuronide epicatechin (4GEC). In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. The compositions are preferably administered orally as a food product in which the 4?-Oglucuronide is present in a concentration of at least 0.01 mg/g of the food product.
    Type: Application
    Filed: December 15, 2016
    Publication date: January 3, 2019
    Applicant: NESTEC S.A.
    Inventors: Lucas Actis Goretta, Amaury Patin, Stephanie Michlig Gonzalez, Susana Camacho, Coline Legrand, Johannes Le Coutre, Euridice Castaneda Gutierrez, Irma Silva Zolezzi